^
Association details:
| Biomarker: | HER-2 overexpression |
|---|---|
| Cancer: | Gastric Adenocarcinoma |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
12/23/2020
Excerpt:
Gastric Cancer: Principles of systemic therapy...Preferred regimens…HER2 overexpression positive adenocarcinoma…Fluoropyrimidine (fluorouracil or capecitabine) and oxaliplatin and trastuzumab...Fluoropyrimidine (fluorouracil or capecitabine) and cisplatin and trastuzumab (Category 1)...Other Recommended Regimens (trastuzumab should be added to first-line chemotherapy for HER2 overexpression positive adenocarcinoma)…Fluorouracil and Irinotecan...Paclitaxel with or without cisplatin or carboplatin...Docetaxel with or without cisplatin...Fluoropyrimidine (fluorouracil or capecitabine)...Docetaxel, cisplatin or oxaliplatin, and fluorouracil
Secondary therapy:
cisplatin + capecitabine; paclitaxel; CAPOX; cisplatin + 5-fluorouracil; cisplatin + docetaxel; carboplatin + paclitaxel; 5-fluorouracil + oxaliplatin; cisplatin + paclitaxel; 5-fluorouracil; 5-fluorouracil + irinotecan; docetaxel + 5-fluorouracil + oxaliplatin; docetaxel; carboplatin + docetaxel + 5-fluorouracil; cisplatin + docetaxel + 5-fluorouracil; capecitabine
Source:
Excerpt:
...the guidelines recommend the addition of trastuzumab to first-line chemotherapy (category 1 for combination with cisplatin and fluoropyrimidine; category 2B for combination with other chemotherapy agents) for patients with HER2-positive metastatic gastric adenocarcinoma...
Excerpt:
Herceptin should only be used in patients with metastatic gastric cancer whose tumours have HER2 overexpression...
Source:
Title:
Investigation of the Proportion of Human Epidermal Growth Factor Receptor 2 Protein Overexpression of Gastric Adenocarcinoma and Prognostic Effect of HER2, and Analysis of Practice Pattern of Herceptin Use in Stage IV Gastric Cancer
Excerpt:
...The proportion of HER2 overexpression in gastric cancer patients...
Trial ID:
Source:
Title:
A pilot study of trastuzumab monotherapy in patients who progressed under a previous platinum-based or 5-fluoropyrimidin-based chemotherapy in metastatic or locally advanced gastric cancer
Excerpt:
...Age > 18 years (ethnical group: any; gender: female and male) Progression under or after one prior platinum-based or 5-fluoropyrimidine-based chemotherapy in metastatic disease At least four weeks from the last platinum-based or 5-fluoropyrimidin-based chemotherapy Histological proof of gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction with HER2 overexpression of the primary or metastatic tumor tissue determined by immunohistochemistry and FISH (Score IHC 3+ or Score IHC 2+ and FISH +) Metastatic (M1) or locally advanced disease At least one measurable lesion evaluable for response (RECIST criteria) Estimated life expectancy of > 3 months ECOG Performance Status: 0-2 Adequate cardiac function: LVEF > 50% (detected by echocardiogram) Absolute neutrophil count > 1,500/µl Absolute platelet count > 100,000 /µl Serum total bilirubin: < 2.0 x upper normal limit (UNL) Creatinine < 1.5 x UNL AST and ALT < 2.5 x UNL; < 5 x UNL in patients with documented liver metastases Alkaline phosphatase: < 2.5 UNL Negative pregnancy test Willingness to give written informed consent, written consent for data protection and willingness to participate and comply with the study...
Trial ID:
